Skip to main content
Clinical Trials/NCT01897103
NCT01897103
Completed
Not Applicable

Platelet Activity in Vascular Surgery

NYU Langone Health2 sites in 1 country200 target enrollmentJune 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Peripheral Vascular Disease
Sponsor
NYU Langone Health
Enrollment
200
Locations
2
Primary Endpoint
Platelet Activity
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The proposed PIVOTAL study will examine a panel of platelet/coagulation activity markers during the perioperative period. The goal is to develop a clinically useful assessment of platelet/coagulation activity for risk stratification that may ultimately serve as a target for therapeutic intervention. This study will enroll 200 patients with peripheral artery disease undergoing vascular surgery. PIVOTAL is funded by American Heart Association and is scheduled to begin enrollment in July 2013 for approximately two years.

Detailed Description

To describe platelet activity among PAD subjects undergoing vascular surgery. To determine whether preoperative platelet activity measurements are independently associated with perioperative cardiovascular events. To identify demographic, clinical, and surgical factors associated with postoperative platelet activity measurements in patients with established PAD.

Registry
clinicaltrials.gov
Start Date
June 2013
End Date
December 2017
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subjects undergoing non emergent vascular surgery
  • Use of aspirin within 48 hours prior to surgery
  • Age \> 21 years of age
  • Able and willing to provide written informed consent for the study

Exclusion Criteria

  • Use of any anticoagulant (Coumadin, heparin) within 24 hours to surgery
  • Use of any Nonsteroidal Antiinflammatory Drug (NSAID) (such as ibuprofen, naproxen, etc.) within 72 hours
  • Thrombocytopenia (platelet count\<100) or Thrombocytosis (platelet count\>500),
  • Anemia (hemoglobin\<9),
  • Severe kidney disease (CrCl\<30ml/min),
  • Any known hemorrhagic diathesis.

Outcomes

Primary Outcomes

Platelet Activity

Time Frame: two years

The main outcome measures are platelet activity, coagulation markers, platelet mapping and profiling.

Secondary Outcomes

  • Perioperative Events(Two-years)

Study Sites (2)

Loading locations...

Similar Trials